TITLE

Dyspepsia management in the millennium: to test and treat or not?

AUTHOR(S)
Delaney, B.C.
PUB. DATE
January 2003
SOURCE
Gut;Jan2003, Vol. 52 Issue 1, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the cost effectiveness of testing and treating uninvestigated dyspepsia with endoscopy for non-responders compared with empiric proton pump inhibitor (PPI) treatment followed by endoscopy, or with strategies of test and treat followed by empiric PPI, with endoscopy reserved for persistently symptomatic patients. Model's use of serology for Helicobacter pylori testing.
ACCESSION #
9758394

 

Related Articles

  • IS OESOPHAGEAL DILATATION A DYING SKILL? THE IMPACT OF PROTON PUMP INHIBITORS. Berry, P.A.; McNeil, N.I. // Gut;Apr2003 Supplement 1, Vol. 52, pA72 

    The number of endoscopic oesophageal dilatations performed for benign stricture was observed to have decreased in our unit over the past decade, making it hard for trainees to gain experience. This trend was investigated, and compared to the rise in the use of proton pump inhibitors (PPIs)....

  • Omeprazole was effective in the short term for uninvestigated dyspepsia. Rabeneck, L.; Souchek, J.; Wristers, k.; Talley, Nicholas J. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p70 

    Summarizes a study that determined whether a proton-pump inhibitor is effective in the treatment of patients with uninvestigated dyspepsia. Characterization of the patients; Main outcome measures; Results of the study.

  • Step up vs step down.  // Infectious Disease Alert;Mar2009 Pharmacology Watch, p2 

    The article discusses research being done on dyspepsia treatment. It references a study by S. V. van Zanten, published in a 2009 issue of "Lancet." The study conducted in the Netherlands focused on dyspepsia patients who were randomized to undergo treatment with an antacid, H2-receptor...

  • Step up vs step down. Elliott, William T. // Clinical Oncology Alert;Mar2009 Pharmacology Watch, p2 

    The article discusses the study about treating patients with dyspepsia conducted in Netherlands. In the study, patients in random order were treated with an antacid, H2-receptor antagonist, and proton pump inhibitor. The study's primary result was symptom relief and cost-effectiveness of initial...

  • To Establish the Efficacy of PPI Therapy for Ulcer Bleeding in the United States, Do We Need More Patients or More PPIs? Leontiadis, Grigoris I.; Howden, Colin W. // American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p2000 

    Proton pump inhibitor (PPI) therapy is widely used in the management of patients with ulcer bleeding. However, most randomized controlled trials (RCTs) have been conducted outside of the United States. Jensen and colleagues have conducted the first United States-based RCT to compare a PPI with...

  • A Cost-Effectiveness Analysis of Prescribing Strategies in the Management of Gastroesophageal Reflux Disease. Gerson, Lauren B.; Robbins, Anthony S.; Garber, Alan; Hornberger, John; Triadafilopoulos, George // American Journal of Gastroenterology;Feb2000, Vol. 95 Issue 2, p395 

    OBJECTIVE: Patients who have uncomplicated gastroesophageal- reflux disease (GERD) typically present with heartburn and acid regurgitation. We sought to determine the cost-effectiveness of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as first-line empiric therapy for...

  • BARRETT'S OESOPHAGUS—IS SURVEILLANCE REQUIRED? Gupta, S.; Fernandez, C.; Arnaout, A.; Theodossi, A.; Mendall, M.A. // Gut;Apr2003 Supplement 1, Vol. 52, pA43 

    Introduction: Controversy exists about the utility of a screening endoscopy programme and the value of proton pump inhibitors (PPI) in preventing the progression from metaplasia to dysplasia to cancer in Barrett's oesophagus (BO). Earlier studies to determine the risk of oesophageal...

  • Intravenous omeprazole acts more rapidly in H. pylori positve patients with peptic ulcer bleeding. Leodolter, A.; Glasbrenner, B.; Peitz, U.; Treiber, G.; Kahl, S.; Malfertheiner, P. // Gut;Sep2002 Supplement 2, Vol. 51, pA94 

    Intravenous proton pump inhibitor (PPI) therapy is the standard medical therapy in conjunction with endoscopic intervention for patients with peptic ulcer bleeding. PPI's are more effective in H. pylori positive patients, but up to now this effect has been observed following an extended period...

  • A Review of the Management of Gastric Acid-Related Diseases: Focus on Rabeprazole. Kusano, Motoyasu; Kuribayashi, Shikou; Kawamura, Osamu; Shimoyama, Yasuyuki; Hosaka, Hiroko; Nagoshi, Atsuto; Zai, Hiroaki; Mori, Masatomo // Clinical Medicine Insights: Gastroenterology;2011, Vol. 2, p31 

    Current treatment guidelines for acid-related diseases (ARDs) recommend first-line treatment with a proton pump inhibitor (PPI) to reduce gastric acid production. PPIs are indicated in the management of gastroesophageal reflux disease (reflux esophagitis, nonerosive reflux disease), peptic ulcer...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics